Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
Open Medicine : a Peer-Reviewed, Independent, Open-Access Journal|July 11, 2014
Travel-acquired infections and illnesses in Canadians: surveillance report from CanTravNet surveillance data, 2009-2011Andrea K Boggild, Jennifer Geduld, Michael Libman, et al.
Journal of Clinical Microbiology|June 26, 2009
Leishmania OligoC-TesT as a simple, rapid, and standardized tool for molecular diagnosis of cutaneous leishmaniasis in PeruDiego Espinosa, Andrea K Boggild, Stijn Deborggraeve, et al.
The Lancet. Neurology|April 6, 2015
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparatorJacqueline Palace, Martin Duddy, Thomas Bregenzer, et al.
Journal of Travel Medicine|January 7, 2012
Latitudinal patterns of travel among returned travelers with influenza: results from the GeoSentinel Surveillance Network, 1997-2007Andrea K Boggild, Francesco Castelli, Philippe Gautret, et al.
Vaccine|September 21, 2010
Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance NetworkAndrea K Boggild, Francesco Castelli, Philippe Gautret, et al.
CMAJ Open|April 7, 2015
Dermatoses among returned Canadian travellers and immigrants: surveillance report based on CanTravNet data, 2009-2012Michael S Stevens, Jennifer Geduld, Michael Libman, et al.
Canada Communicable Disease Report = Releve Des Maladies Transmissibles Au Canada|May 18, 2018
Illness in Canadian travellers and migrants from Brazil: CanTravNet surveillance data, 2013-2016A K Boggild, J Geduld, M Libman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 23, 2018
Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing schemeJacqueline Palace, Martin Duddy, Michael Lawton, et al.
Neurology|July 29, 2011
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohortM Cossburn, A A Pace, J Jones, et al.
Infection|August 9, 2021
Evaluation of a point-of-care molecular detection device for Leishmania spp. and intercurrent fungal and mycobacterial organisms in Peruvian patients with cutaneous ulcersRuwandi Kariyawasam, Braulio M Valencia, Rachel Lau, et al.
Pageof 25